CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0269 (clinicaltrials.gov NCT No: NCT01375140)
Title:EVALUATION OF RUXOLITINIB AND LENALIDOMIDE COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS
Principal Investigator:Srdan Verstovsek
Treatment Agent:Lenalidomide; Prednisone; Ruxolitinib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the combination of
ruxolitinib and lenalidomide can help to control MF. The safety of this study
drug combination will also be studied.

Ruxolitinib is designed to stop certain proteins (called JAK1 and JAK2) that
are found in MF cells from sending signals that may lead to the growth of
cancer cells.

Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may decrease the growth of cancer cells.

Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:Lenalidomide
Prednisone
Ruxolitinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Incyte Corporation
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults